Synaptic Pharmaceutical / Lundbeck Research USA, Paramus • NJ 2002 — 2006 Research Associate Facilitated with assistance in the evaluation and implementation of one
new cytotoxicity assay to support compound profiling efforts within projects.
Not exact matches
A
new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine - induced antigen and that the level of induced expression is sufficient to trigger
cytotoxicity in patient - derived vaccine - induced T cells.
T lymphocytes can recognize these
new or altered antigens and are able to fight tumour through direct
cytotoxicity or cytokine secretion.